SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.
SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.
Active, not recruiting · NCT05022654 · Registry updated 2025-09-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. | Esophageal Squamous Cell Carcinomas | Active, not recruiting | Phase 2 | 2025-09-26 | NCT05022654 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sichuan Baili Pharmaceutical Co., Ltd. | 135 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Anyang Cancer Hospital of Henan Province | Anyang | China | 1 |
| Beijing Cancer Hostital | Beijing | China | 1 |
| Shanxi Cancer Hospital | Taiyuan | China | 25 |
| Suining Central Hospital | Suining | China | 5 |
| The First Affiliated Hospital of Henan University of Science and Technology | Luoyang | China | 28 |
| Xuzhou Central Hospital | Xuzhou | China | 23 |